ITEM logo

ITEM

A PHASE II STUDY OF IMATINIB IN THE TREATMENT OF PATIENTS WITH METASTATIC UVEAL MELANOMA

ITEM

A PHASE II STUDY OF IMATINIB IN THE TREATMENT OF PATIENTS WITH METASTATIC UVEAL MELANOMA
Funding
Portfolio Cancer
Interventions Medicine
Randomised No
Status Closed
Start Date 19-Aug-2008

Uveal melanoma is the most common primary malignancy involving the eye, but remains rare, with an annual age-adjusted incidence of around 7 per million of the population1. Ocular melanomas can involve any part of the uveal tract i.e. the choroid, ciliary body or iris. On clinical, biological and molecular grounds, uveal melanoma is a separate disease distinct from cutaneous melanoma. Approximately 5% of patients present with metastatic disease. A further 30-50% develop metastatic disease, usually within 3 years of primary treatment2. There is no effective systemic therapy for metastatic uveal melanoma. Furthermore, few clinical trials have been conducted, and those which have, often involve small numbers of patients.